Insider · CIK 0001720974
Ankit Mahadevia
director
Files at SPRO (Spero Therapeutics, Inc.). First filing Sep 3, 2025, latest Sep 3, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $13k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SPRO: Spero Therapeutics, Inc.
SPROOct 9, 2026 · close 1.20
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | Spero Therapeutics, Inc. | $13k 6,572 shares | -1% | +257% from low-34% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 28, 2025 | SPRO Spero Therapeutics, Inc. | SOpen-market sale Common Stock | -6,572 | $1.97 | $13k | 703,294 | Sep 3, 2025 |
| Jun 12, 2025 | SPRO Spero Therapeutics, Inc. | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 709,866 | Jun 16, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.